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Purpose: In newly diagnosed patients with Dravet syndrome sodium channel blockers are usually
avoided. However, in many adult patients the diagnosis was made long after the initiation of therapy.
The purpose of our study was to acquire information concerning the potential risks and beneﬁts of
(ox)carba(ma)zepine withdrawal in adult patients with genetically conﬁrmed Dravet syndrome.
Method: We identiﬁed 16 adults with Dravet syndrome, living in a tertiary care facility for people with
epilepsy and an intellectual disability. We reviewed clinical history, genetic ﬁndings, the type and
duration of sodium channels blockers that were used, seizure types and frequency, and the effect of a
change in these medications.
Results: The study population consisted of 9 men and 7 women. Median age was 35 years (range 20–61
years).
An attempt to withdraw carbamazepine (CBZ) was made in 9 patients. In 3 of these patients an
increase in tonic-clonic seizures was observed. An attempt to withdraw oxcarbazepine (OXC) was made
in 3 patients, leading to a complete stop in 2 patients.
3 of the 4 deaths in the withdrawal-group were related to epilepsy.
Conclusion: In adult patients with Dravet syndrome withdrawal of CBZ or OXC is not without risks. We
suggest that (ox)carba(ma)zepine withdrawal should be considered in these patients but only if there is a
good reason to do so and only if they are closely monitored.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Dravet syndrome is a severe epileptic encephalopathy, most
frequently caused by a mutation in the SCN1A gene. It is
characterized by onset of recurrent febrile and/or afebrile
hemiclonic or generalized seizures in a previously healthy infant
in the ﬁrst 15 months of their life. This is usually followed by
appearance of multiple seizure types, generally resistant to anti-
epileptic drugs, with developmental arrest or regression [8,7].
Epileptic seizures often encountered are atypical absences, tonic
seizures, myoclonic seizures and tonic clonic seizures. The tonic
clonic seizures with a focal onset persist into adulthood but with
increasing age there is a reduction in the number of atypical
absences and myoclonic seizures. In addition to the seizures and* Corresponding author at: Sterkselseweg 65, 5590 AB Heeze, The Netherlands.
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1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights recognitive impairment, a progressive loss of mobility is seen partly
due to cerebellar impairment [15]. Prognosis is bleak with a
mortality rate, also in the adult group, between 15 and 20% [10].
Most of these deaths are related to complications of a status
epilepticus or due to ‘sudden unexpected death in epilepsy (SUDEP)’.
There is evidence for the efﬁcacy of stiripentol (STP), based on
two randomized controlled trials. In these add-on trials STP was
added to a treatment regime with valproate and clobazepam
(STICLO France, Lancet 2000, STICLO Italy (not published)).
Levetiracetam, topiramate and zonisamide appear to be helpful,
but clinical evidence is weak (or randomized trials are not
available). In addition, there are ‘medication to avoid’ especially
concerning lamotrigine, phenytoin and carbamazepine. For
lamotrigine this was carefully documented by Guerrini et al.
[11]. They found an increase of tonic clonic and myoclonic seizures
in 17 of the 21 patients with Dravet syndrome who were on
lamotrigine. However, for the advice to avoid phenytoin and
carbamazepine, there is less scientiﬁc evidence.served.
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frequency by sodium channel blockers is based on the expression
pattern of the SCN1A mutation [5]. The SCN1A gene codes for the
SCN1 alpha protein, a subunit of the voltage gated sodium channel.
Voltage gated channels are the basis for every action potential,
explaining their relation with epilepsy. Dravet syndrome is usually
caused by ‘loss of function’ mutations and for this a loss of
excitation would be expected. However, SCN1A mice models show
a loss of excitation of the GABA-ergic interneurons without a
relevant effect of the SCN1A mutation on the excitatory pyramidal
neurons [19]. So, in the mouse model the epilepsy is explained by a
loss of inhibition of the GABA-ergic interneurons. The use of
sodium channels blockers will, in this model, further reduce the
already impaired inhibition. Benzodiazepines and stiripentol are
assumed to be effective because of their GABA-ergic effect. Drugs
like levetiracetam, topiramate, valproate en zonisamide have an
indirect effect on GABA-ergic neurons that might explain their
efﬁcacy.
A negative effect of carbamazepine was reported in the large
series of Brunklaus et al. [3], where carbamazepine was the drug
that was most often associated with a paradoxical effect.
Supported by these data we decided to withdraw carbamaze-
pine in one of our adult patients with Dravet syndrome, who was
on polytherapy and had frequent myoclonic seizures. The effect of
carbamazepine withdrawal was a reduction in myoclonic seizures
but an increase of tonic seizures. These tonic seizures evolved into
a status epilepticus which was complicated by a bilateral
pneumonia, due to which the patient ultimately died. Based on
this experience we decided to investigate the effect of medication
alteration, in particular the withdrawal of carbamazepine (CBZ)
and oxcarbazepine (OXC) on seizure type and seizure frequency in
adult patients with Dravet syndrome.
2. Material and methods
The digital medical records of all our adult patients living in
Kempenhaeghe (a tertiary care facility for people with epilepsy and
an intellectual disability) with a genetically conﬁrmed diagnosis of
Dravet syndrome, were reviewed. Diagnostic criteria for Dravet
syndrome as proposed by Dravet et al. [8] were used in addition to
the SCN1A mutation. Out-patients were excluded, as were patients
with an epileptic encephalopathy not related to Dravet syndrome.Table 1
Demographics.
Case Gender/
age
Age of
onset
(months)
Intellectual
disability
SCN1A mutation Seizu
in ad
1 M/20 6 Severe c.3370-3371delTT MY, T
2 F/21 4.5 Severe c.694 + 1 G > C GC, G
3 M/21 9 Moderate c.580 G > A FS, C
4 M/22 5 Profound c.2686 G > T GC, G
5 F/25 9 Moderate c.664 C > T MY, G
6 M/26 9 Severe c.2202 C > A GTC, 
7 F/28 4 Moderate c.2589 + 3 A > T GTC, 
8 M/33 4 Profound c.4094 G > A CP, G
9 M/37 18 Severe c.248 A > G GTC, 
10 F/37 7 Moderate c.1258dup ‘‘drop
11 M/39 14 Severe c.5564 C > A GTC, 
12 F/46 8 Severe c.5422 T > C CP, G
13 M/51 6 Severe c.4628 T > C GTC, 
14 M/51 8 Severe c.1166_1170 + 2del GTC, 
15 M/52 6 Profound c.5604 A > C CP, G
16 F/61 9 Moderate c.2425 G > A GTC, 
M = male, F = female, CP = complex partial, FO = focal, FS = febrile seizures, GC = generalize
attacks’, CBZ = carbamazepine, CLB = clobazam, CLN = clonazepam, ESM = ethosuxim
OXC = oxcarbamazepine, PHB = Fenobarbital, PHT = Phenytoin, STP = stiripentol, TPM = toWe identiﬁed 16 adult patients. Information concerning gender,
age, age at onset, type of SCN1A mutation, severity of intellectual
disability, and mortality were documented.
In addition, the treatment, duration of treatment with CBZ/OXC
and the effect of a change in these medications on seizure type and
seizure frequency were noted. Digital medical and pharmacy
records, including a graphical rendering of seizure type and
frequency, were available since 1992.
All available clinical and investigational information was
reviewed.
Seizure types in adulthood where all classiﬁed by the
neurologist in the past. In many cases video-EEG did not cover
all seizure types.
Seizure frequency and type of seizures as it was documented
over the years by the nursing staff was carefully studied but the
conclusion whether there was a change in seizure type and
frequency after the start or withdrawal of CBZ/OXC was ultimately
based on the documented (written) clinical judgement of the
consultant neurologist at the time of the anti-epileptic drug
adjustment.
To identify if the seizure frequency was ‘‘increased’’ or
‘‘decreased’’, we used a time-frame of 3 months of clinical data
after the last dosage reduction or complete stop. Possible related
clinical factors, when documented were collected in the database.
3. Results
The study population consisted of 10 men and 6 women.
Demographic and clinical data are summarized in Table 1. Median
age was 35 years (range 20–61 years).
3.1. Carbamazepine (CBZ)
A total of eleven patients in the study-population (68.75%) used
CBZ during their lifetime.
Details are presented in Table 2.
In nine of these patients, an attempt to withdraw CBZ was made
at some stage. In six patients CBZ was completely stopped. The
reason to withdraw the medication varied from ‘no efﬁcacy’, ‘side
effects’ to ‘based on the current literature’. In three of the nine
patients (33%), an increase in tonic clonic seizures was noted.
In three patients (case 1.4 and 9) the CBZ was replaced by either
Lamictal (case 1) or Stiripentol (case 4 and 9), in the six otherre types
ulthood
All known previous AED-history
 ZNS, LEV, TPM, PHB, CLN, LTG, FBM, CLB, PHT, CBZ, VPA
TC, FO, T LTG, VPA, STP, CLN
P TPM, CLN, LTG, CBZ, PHB, VPA
TC, ‘drops’, T ZNS, VPA, LEV, CLN, CLB, CBZ, STP, GBP, TPM, LTG, PHB, VGB
TC CBZ, VPA, LTG, CLN, TPM, CLB, VGB, PHT
FO, T VPA, OXC, LEV, TPM, CLN, CLB
MY LTG, VPA, GBP, ESM, VGB, Diamox
TC, MY, GC, T LEV, CLN, CBZ, VPA, TPM, GBP, LTG, VGB
MY, T STP, TPM, VPA, CLB, GBP, LEV, PHB, LTG, VGB, CBZ
s’’, MY, T CLB, TPM, CLN, VPA, VGB, ESM, CBZ
MY, T LEV, VPA, TPM, LTG, FBM, CLB, VGB, OXC
TC, MY, GC, T LEV, CLN, CBZ, VPA, VGB, ESM, LTG, Diamox
‘‘drops’’ VPA, CLB, PHT, LTG, GBP, CBZ
GC, MY, T ZNS, LEV, VPA, CLN, PHB, LTG, FBM, CLB, VGB, OXC
TC, MY, GC, T STP, CLN, PHB, VPA, LEV, CLB, TPM, CBZ, LTG
MY LTG, CLB, CBZ, VPA, VGB, OXC
d clonic, GTC = generalized tonic-clonic, MY = myoclonic, T = tonic, ‘‘drops’’ = ‘drop-
ide, FBM = Felbamate, GBP = gabapentin, LEV = levetiracetam, LTG = lamotrigine,
piramate, VGB = Vigabatrin, VPA = Valproate, ZNS = Zonisamide.
Table 2
Carbamazepine (CBZ) treatment.
Case Current
CBZ
treatment
Total duration
of CBZ
treatment
(years)
Co-medication during
CBZ treatment
CBZ stop/reduction Withdrawal/
reduction
period
(months)
Outcome after
stop/reduction
Cause of death
(age at death, in years)
1 N 0.9 VPA, PHTa Stop (500–0 mg) 2 Seizure control
unchanged
Testicular cancer (20 years)
3 N 2.3 PB, PHT, LTGa, VPA Stop (200–0 mg) 0 Seizure-free
4 Y 18 VPA, ZNSa, LEV, STPa, CLBa Reduction (300–100 mg) 9 Status epilepticus Bronchopneumonia during
recurrent convulsive status
epilepticus (22 years)
5 Y 8.4 VPAa, LTGa, CLNa Reduction (600–300 mg) 13 Unknown SUDEP 2 years after
CBZ reduction (25 years)
8 Y >20 VPA, VGB, LTG, LEV, TPM,
GBP, CLN
No change
9 N >20 GBP, VGB, LTG, LEV VPAa,
PB, mysoline, PHT, CLBa,
CLN, TPMa, STP
Stop (600–0 mg) 7 Myoclonic status#,
tonic seizures#
10 N 12 LTGa, VPAa, ESM, VGB, CLN Stop (500–0 mg) 1 GTC seizures"
12 Y >20 ESM, VGB, CLZ, VPA, LEV, LTG,
CLB, acetazolamide
No change
13 N 6.4 PHTa, LTGa, CLBa Stop (400–0 mg) 1 Unknown
15 N >20 PHBa, CLBa, TPM, LTG, VPAa,
LEV, acetazolamide, STP
Stop (500–0 mg) 5 Tonic seizures#,
GTC seizures"
16 Y >20 VPAa, LTGa, CLBa, PHT,
OXC, VGB
Reduction (900–300 mg) 4 GTC seizures "
N = no, Y = yes, # = decreased, " = increased.
a (BOLD) = co-medication at time of reduction/withdrawal.
CBZ = carbamazepine, CLB = clobazam, CLN = clonazepam, ESM = ethosuximide, FBM = felbamate, GBP = gabapentin, LEV = levetiracetam, LTG = lamotrigine, OXC = oxcarba-
zepine, PHB = fenobarbital, PHT = phenytoin, PRM = primidone, STP = stiripentol, TPM = topiramate, VGB = vigabatrin, VPA = valproate, ZNS = zonisamide, GTC = generalized
tonic-clonic.
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after reduction or withdrawal.
In patient number 4 a possible precipitating factor of seizure
aggravation was a recent fever period caused by a respiratory tract
infection. In the other patients no possible related clinical factor
during the reduction/withdrawal period was documented in the
medical records.
3.2. Oxcarbazepine (OXC)
A total of ﬁve patients in the study-population (31.25%) used
OXC during their lifetime.
Details are presented in Table 3.
In three patients an attempt to withdraw was made, in two
patients a complete stop was possible.
In one patient the myoclonic seizures reduced after the
complete stop, in the other patient there was no change in seizure
control.Table 3
Oxcarbazepine (OXC) treatment.
Case Current
OXC
treatment
Total duration
of OXC
treatment
(years)
Co-medication during
OXC treatment
OXC stop/
5 N 2 CBZ, VPA, LTG, CLN Stop (900
6 Y >20 VPA, LEV, TPM, CLN, CLB No chang
11 Y >20 LEV, VPA, TPM, LTG, CLB,
FBM, VGB
No chang
14 Y >20 ZNSa, LEVa, VPAa, CLNa,
PHBa, LTG, FBM, CLB, VGB
Reduction
16 N 0.1 VPAa, CBZa Stop (120
N = no, Y = yes, # = decreased, " = increased.
a (BOLD) = co-medication at time of reduction/withdrawal.
CBZ = carbamazepine, CLB = clobazam, CLN = clonazepam, FBM = Felbamate, LEV = levetir
VPA = Valproate, ZNS = Zonisamide, GTC = generalized tonic-clonic, MY = myoclonic.In one patient (case 5) the OXC was replaced by CBZ, in the other
2 patients (case 14 and 16) the OXC was not replaced by another
anti-epileptic drug after reduction or withdrawal.
In patient number 14 a possible precipitating factor of seizure
aggravation was a recurrent respiratory tract infection and feeding
problems.
In the other patients no possible related clinical factor during the
reduction/withdrawal period was documented in the medical records.
3.3. Mortality
Four patients died in total. Three of the four deaths were related
to epilepsy.
In two patients the status epilepticus, either convulsive or
myoclonic, was complicated by a bilateral pneumonia. Both
patients had a previous status epilepticus during their lifetime.
In one of these two patients the ﬁnal status epilepticus
developed during the reduction of OXC.reduction Withdrawal/
reduction
period
(months)
Outcome after
stop/reduction
Cause of death
(age at death, in years)
–0 mg) 1 Seizure control
unchanged
SUDEP 2 years after
CBZ reduction (25 years)
e
e
 (600–0 mg) 3 GTC seizures "
0–0 mg) 1 MY #
acetam, LTG = lamotrigine, PHB = Fenobarbital, TPM = topiramate, VGB = Vigabatrin,
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reduction of CBZ.
4. Discussion and conclusion
The withdrawal of carbamazepine in our institutionalized adult
Dravet patients induced an increase of tonic clonic seizures in three
out of nine subjects. In one patient the withdrawal of carbamaze-
pine was, in time, related to an increase of convulsive seizures that
attributed to her death. Although our experience is based on a
small population the study is, in a way, unbiased as we included all
our institutionalized adult SCN1A positive Dravet patients. Still,
due to the retrospective nature of the study, the results should be
interpreted with care.
Our retrospective data appears to be in contrast with the
available, also retrospectively acquired, data from the literature. In
2011, Dravet and Guerrini [9] referred to three publications that
suggest a deterioration of seizure control after the start of
carbamazepine. In one of these publications [16] (N = 6) there
was a deterioration of seizure control in four patients and no effect
in two subjects. In the second publication [12] (N = 9) carbamaze-
pine induced an increase of seizure frequency in two, side effects in
ﬁve, and a positive effect in two patients. The third publication [17]
(N = 10) showed a similar result. In addition to these studies, there
are two relatively recent large ‘clinical’ Dravet studies [3,18]
looking at the effect of medication. In the manuscript by Brunklaus
et al. [3] (N = 241), there were sixty patients who showed a
deterioration after the start of medication. In thirty-six of these
sixty patients (60%) the deterioration was caused by carbamaze-
pine. However, it was not described how often a positive or
equivocal effect was seen. In the study by Xu (N = 138), forty
patients were treated with carbamazepine of whom sixteen (40%)
showed an increase in seizure frequency. There was no effect of
carbamazepine in the other twenty-four patients.
There are various possible explanations for the differences in
outcome between these studies and our results. First, in the
previous studies, the effect of carbamazepine was studied in
patients in whom carbamazepine was started, not in patients
where it was discontinued. Secondly, in the literature the focus is
on children whereas in our study we only included adult patients.
This might be relevant as the chance of secondary lesions inducing
a change in seizure type that is responsive to carbamazepine is
higher in the adult group. This hypothesis is supported by the high
percentage of patients with tonic seizures that was encountered in
our adult patients, a type of seizure that is only rarely observed in
children with Dravet syndrome or in previously studied adult
patient groups. However, as was pointed out by several authors:
‘‘Some of the major convulsive seizures in adult DS have less
typical aspects, for example, bilateral or asymmetric tonic
posturing followed in some cases by a tonic vibratory state or
clonic movements’’ [1,10,14]. For this, it is possible that the
convulsive seizures that in our institute were classiﬁed as tonic,
could in some cases also have been classiﬁed as ‘atypical tonic
clonic’. We also have to take into account that, in addition, a
difference in age could be accompanied by a change in the
expression of the SCN1A gene.
The expression of sodium channels is age-dependent, which
explains the age of seizure onset after an initially normal
development [5]. In Dravet syndrome, seizure patterns change
with age. In adult patients convulsive and dyscognitive seizures
may become prominent. Serial interictal or ictal EEGs tend to show
evidence a focal onset, while myoclonic seizures, atypical absences
and photosensitivity eventually diminish or disappear in adult-
hood [1,4,10]. Furthermore, in mouse models, the antiepileptic
efﬁcacy of stiripentol diminishes with age [2] and combinations ofdrugs may be synergistic for one seizure type, but not for another
[13].
Important for the current concept of seizures in patients with
Dravet syndrome is the selective expression of sodium channels.
There are various subtypes with a different regional expression
pattern that is dependent on maturation [5]. It is well possible that
age, chronic polytherapy or secondary neuronal damage change
the expression pattern of ion channels in speciﬁc brain regions that
might disrupt the balance between inhibition and excitation that
will have consequences for the appropriate treatment regime.
Even in the studies that pointed out the risk of carbamazepine
on seizure frequency in patients with Dravet syndrome, there were
some patients in whom the carbamazepine could not be
discontinued. This was well recognized by Dravet who observed
that: ‘‘In some older patient taking polytherapies, including
carbamazepine, lamotrigine and phenytoin, attempt of drug
withdrawal were followed by aggravation of epilepsy’’ [9].
The percentage of 25% patients who died in our study appears
relatively high as compared to the percentage of 15–20% that is
mentioned in the literature [10]. This percentage might be
explained by the small number of patients, the fact that in one
patient the cause of death was not related to epilepsy and the
severity of clinical features of our institutionalized patients. The
study is too small to compare the mortality risk in those patients
who have been on carbamazepine and those who have not.
We conclude that, based on the available literature, there is a
relative contraindication for the use of sodium channel blockers in
newly diagnosed patients with Dravet syndrome. The information
concerning patients 3, 9 and 16 shows that in adult patients, the
reduction of (ox)carba(ma)zepine could lead to a (partially) better
seizure control. However, our data also indicate that the evidence
to withdraw carbamazepine (or oxcarbazepine) is still inadequate
and the withdrawal of these drugs should be very closely
monitored by a neurologist that is aware of both the beneﬁts
and risks. We suggest that (ox)carba(ma)zepine withdrawal
should be considered in these patients but only if there is a good
reason to do so and only if they are closely monitored.
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